Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

Figure 8 Inhibition of AMPK abolished the beneficial effects of teneligliptin against high glucose in cardiomyocytes. Primary cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (5 µM) and compound C (10 μM). A: Levels of p-AMPK; B: The levels of NLRP3; C: Levels of creatine kinase-MB and aspartate transaminase level. ^aP < 0.05 vs control group; ^bP < 0.05 vs high glucose 30 mmol/L group; ^cP < 0.05 vs high glucose 30 mmol/L + teneligliptin 5 µM group, n = 5.